Instituto Médico Catamarca IMEC
Rosario, Argentina
6 recruiting
Showing 1–6 of 6 trials
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,035 enrolled158 locationsNCT07282600
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Chronic Kidney DiseaseAtherosclerosis Cardiovascular Disease
Eli Lilly and Company7,140 enrolled565 locationsNCT07241390
Recruiting
Phase 2
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
Diabetes Mellitus, Type 2
Eli Lilly and Company100 enrolled26 locationsNCT07215312
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
ObesityOverweight
Eli Lilly and Company600 enrolled80 locationsNCT06972459
Recruiting
Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
ObesityOverweightType 2 Diabetes
Eli Lilly and Company1,200 enrolled80 locationsNCT06993792
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
ObesityOverweightType 2 Diabetes
Eli Lilly and Company600 enrolled77 locationsNCT06972472